•  
  •  
 

Authors

Mohamed A. Kharfan-Dabaja, Division of Hematology-oncology and Blood and Marrow Transplantation and Cellular therapy Programs, Mayo Clinic, Jacksonville, FL, USAFollow
Vivek Roy, Division of Hematology-oncology and Blood and Marrow Transplantation and Cellular therapy Programs, Mayo Clinic, Jacksonville, FL, USA
Hemant Murthy, Division of Hematology-oncology and Blood and Marrow Transplantation and Cellular therapy Programs, Mayo Clinic, Jacksonville, FL, USA
Deborah Fischer, Division of Hematology-oncology and Blood and Marrow Transplantation and Cellular therapy Programs, Mayo Clinic, Jacksonville, FL, USA
Razan Mohty, Division of Hematology-oncology and Blood and Marrow Transplantation and Cellular therapy Programs, Mayo Clinic, Jacksonville, FL, USA
Ashley Greathouse, Department of Internal Medicine, Advanced Care at Home Program, Mayo Clinic, Jacksonville, FL, USA
Alethea Brown, Department of Internal Medicine, Advanced Care at Home Program, Mayo Clinic, Jacksonville, FL, USA
Kathryn Moreno, Department of Internal Medicine, Advanced Care at Home Program, Mayo Clinic, Jacksonville, FL, USA
Emily Godsey, Division of Hematology-oncology and Blood and Marrow Transplantation and Cellular therapy Programs, Mayo Clinic, Jacksonville, FL, USA
Jennifer M. Higginbotham, Division of Hematology-oncology and Blood and Marrow Transplantation and Cellular therapy Programs, Mayo Clinic, Jacksonville, FL, USA
Ashley Bartholomew, Division of Hematology-oncology and Blood and Marrow Transplantation and Cellular therapy Programs, Mayo Clinic, Jacksonville, FL, USA
Alexis Jackson, Division of Hematology-oncology and Blood and Marrow Transplantation and Cellular therapy Programs, Mayo Clinic, Jacksonville, FL, USA
Ricardo A. Torres-Guzman, Department of Surgery, Mayo Clinic, Jacksonville, FL, USA
Antonio J. Forte, Department of Surgery, Mayo Clinic, Jacksonville, FL, USA
Sikander Ailawadhi, Division of Hematology-oncology and Blood and Marrow Transplantation and Cellular therapy Programs, Mayo Clinic, Jacksonville, FL, USA
Roxana Dronca, Division of Hematology-oncology and Blood and Marrow Transplantation and Cellular therapy Programs, Mayo Clinic, Jacksonville, FL, USA
Michael Maniaci, Department of Internal Medicine, Advanced Care at Home Program, Mayo Clinic, Jacksonville, FL, USA

Abstract

Multiple myeloma (MM) is the second most common hematologic malignancy with 34,470 estimated new cases in 2022. High-dose therapy followed by autologous hematopoietic cell transplantation (auto-HCT) is a standard treatment for MM even in the era of novel therapies. This is usually done in hospital-based setting, whether in the inpatient or outpatient units. Advanced Care at Home (ACH) represents a virtual hybrid hospital-at-home program that combines a virtual provider-staffed command center with vendor-mediated supply chain capable of delivering high-acuity care in the comfort of patient’s own homes. In our program, we leveraged the existing ACH platform to deliver post-HCT care for recipients of auto-HCT. Four patients (female=2, 50%) with MM with a median age of 60 (range 40-74) years were admitted to the inpatient Blood and Marrow Transplant (BMT) unit. Conditioning regimen consisted of melphalan 200 mg/m2 administered on day -2. All received stem cell infusion (day 0) in the inpatient setting, with a median dose of 3.64 (range, 2.92-8.22) x 106/kg CD34 cells. Patients were discharged to their homes after completion of infusion on day 0 or day +1 at the latest. Post-infusion care was provided by the ACH team in coordination with the BMT team. Median time to ANC and platelets engraftment were 12 (range, 11-13) days and 11 (range, 9-16) days, respectively. All patients were successfully discharged from the ACH program at a median of day +14 (range, day +14 to day +15). Our results highlight the feasibility of delivering post-HCT care for auto-HCT recipients in the home setting and confirm the generalizability of this approach.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Share

COinS